<DOC>
	<DOCNO>NCT00544284</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together temozolomide treat patient brain tumor solid tumor respond treatment .</brief_summary>
	<brief_title>Bortezomib Temozolomide Treating Patients With Brain Tumors Other Solid Tumors That Have Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine dose-limiting toxicity maximum tolerated dos bortezomib temozolomide patient recurrent high-grade glioma , recurrent metastatic brain tumor , refractory solid tumor . Secondary - To evaluate pharmacokinetics bortezomib patient take hepatic enzyme-inducing anticonvulsant ( Group A ) ( Group B ) . - To describe proportion study patient treat bortezomib temozolomide obtain confirm complete response partial response . - To report percentage patient 6-month progression-free survival . OUTLINE : Patients stratify accord concurrent hepatic enzyme-inducing anticonvulsant ( HEIAs ) ( Group A ) versus concurrent anticonvulsant drug cause modest induction hepatic metabolic enzyme OR anticonvulsant drug ( Group B ) . - Group A : Patients receive oral temozolomide day day 1-5 bortezomib IV day 2 , 5 , 9 , 12 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Group B : Patients receive temozolomide bortezomib group A . Cohorts patient group receive escalate dos study drug maximum tolerated dos determine . All patient undergo blood sample collection periodically pharmacokinetic study . Samples analyze bortezomib concentration ( group A B ) trough level anticonvulsant ( group A ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor include follow Recurrent highgrade glioma Recurrent metastatic brain tumor Recurrent primary brain tumor include primary CNS lymphoma Other refractory solid tumor Unresectable disease standard curative palliative measure exist longer effective Measurable nonmeasurable disease PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Total bilirubin ≤ 2.0 mg/dL AST ≤ 4.0 x ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patient must able understand willing sign write informed consent document Exclusion criterion : Any following condition : Myocardial infarction within past 6 month New York Heart Association class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia ECG evidence acute ischemia active conduction system abnormalities Any ECG abnormality prior study entry must document investigator medically relevant Serious medical psychiatric illness would , opinion investigator , potentially interfere completion treatment History sensitivity boron mannitol PRIOR CONCURRENT THERAPY : Inclusion criterion : At least 4 week since prior chemotherapy ( 6 week nitrosoureacontaining chemotherapy ) , immunotherapy , radiotherapy recover More 10 day since prior anticonvulsant drug induce hepatic metabolic enzyme patient group A Recovered major surgery Corticosteroids cerebral edema allow provided patient stable dose least 1 week Exclusion criterion : Patients enrol another clinical trial HIVpositive patient antiretroviral therapy Concurrent chemotherapy radiotherapy Patient require antiseizure medication stable dose agent antiseizure medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>adult melanocytic lesion</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult papillary meningioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>adult pineocytoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
</DOC>